The company is developing highly accurate heart rate measuring technology designed specifically for babies who need stabilisation or resuscitation at birth. One in ten newborns requires such procedures.

It can help reduce the time patients spend in neonatal intensive care and reduce costs for
healthcare organisations.

Accurate, rapid measurements benefit medical staff by enabling them to make confident decisions more quickly and to focus on performing procedures in time critical situations.

• Capital raise: £3 million GBP
• Headquarters: Nottingham, England.
• Type of entity Series: A company
• Use of proceeds: Expansion into US market
• USPs: Low headcount, late-stage, the device
  already in limited use, integrated with major
  players (Phillips)
• Type of investment: Equity
• Geography: Europe/ US
• Annual revenue: USD $3.2m
• Min. ticket size: £500K GBP